Tagged with Bachem

Switzerland Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer, or Breitling, made-in-Switzerland pharmaceuticals do not necessarily come cheap, but the country’s network of life science manufacturers seem content that…

Switzerland Bachem’s Thomas Meier highlights the company’s pivotal role as a CDMO in the rapidly evolving peptide and oligonucleotide markets, emphasizing strategic expansions, innovative manufacturing techniques, and a deep commitment to sustainability. With a vision for growth that includes both profitability and operational excellence, Bachem is poised to lead in therapeutic…

Switzerland Advances in delivery technology and manufacturing costs have driven a surge of activity in peptide drug development, says Thomas Früh, CEO of Bachem –  the largest and most advanced peptide drug CMO in the world. Peptide therapeutics are a hot topic in the pharma industry today – what’s the story…